Alimera Sciences (ALIM) Receives Daily Media Impact Rating of 0.19
News stories about Alimera Sciences (NASDAQ:ALIM) have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Alimera Sciences earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.557485338609 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Alimera Sciences, Inc. (NASDAQ:ALIM) Trading Volume Significantly Lower – First News 24 (firstnewspaper24.com)
- Diabetic Retinopathy Market share to grow at 6.9% CAGR from 2016 to 2023 (openpr.com)
- Earnings Review and Free Research Report: pSivida’s Revenue Surged 52.2%; Net Loss Narrowed (money.ca)
- Alimera Sciences Announces Four Data Sets for ILUVIEN® to Be Presented at 2017 Retina Society’s Annual Meeting – Nasdaq (nasdaq.com)
- Mirna Therapeutics (SYBX) and Alimera Sciences (ALIM) Critical Survey (americanbankingnews.com)
Several equities research analysts recently commented on the stock. Cowen and Company reissued a “buy” rating and set a $3.00 price objective on shares of Alimera Sciences in a research note on Tuesday, July 11th. HC Wainwright set a $5.00 price objective on shares of Alimera Sciences and gave the stock a “buy” rating in a research note on Wednesday, July 26th. Zacks Investment Research lowered shares of Alimera Sciences from a “hold” rating to a “sell” rating in a research note on Thursday, August 17th. Finally, ValuEngine raised shares of Alimera Sciences from a “sell” rating to a “hold” rating in a research note on Thursday, July 13th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. Alimera Sciences has a consensus rating of “Hold” and an average price target of $3.38.
Alimera Sciences (NASDAQ ALIM) traded up 1.095% during midday trading on Friday, reaching $1.385. 84,613 shares of the company traded hands. The stock’s market capitalization is $95.63 million. Alimera Sciences has a one year low of $1.03 and a one year high of $1.72. The company has a 50 day moving average price of $1.38 and a 200-day moving average price of $1.43.
Alimera Sciences (NASDAQ:ALIM) last released its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. The firm had revenue of $10.40 million during the quarter, compared to the consensus estimate of $10.20 million. The firm’s quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.17) earnings per share. Analysts forecast that Alimera Sciences will post ($0.21) EPS for the current fiscal year.
WARNING: This article was reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.watchlistnews.com/alimera-sciences-alim-receives-daily-media-impact-rating-of-0-19/1616119.html.
Alimera Sciences Company Profile
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.